All In Biotech

Drug Trial Radar · NCT07674667

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of TRCN-1023 Administered by Intrathecal Injections to Adult People Living With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Trace Neuroscience, Inc.Industry
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • TRCN-1023Drug

    TRCN-1023 administered as an intrathecal injection.

  • PlaceboOther

    Intrathecal injection of artificial cerebrospinal fluid (aCSF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse EventsTime frame: 24 Weeks

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • TUM Klinikum Rechts der Isar

    Munich, Germany · Recruiting

  • University Medical Center Rostock

    Rostock, Germany · Recruiting

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Schleswig-Holstein, Germany · Recruiting

  • University Medical Center Utrecht

    Utrecht, Netherlands · Recruiting

  • University College London

    London, United Kingdom · Recruiting

  • University of Sheffield

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.